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Little is known about the genotypic make-up of HIV-1 DNA genomes during the earliest
stages of HIV-1 infection. Here, we use near-full-length, single genome next-generation
sequencing to longitudinally genotype and quantify subtype C HIV-1 DNA in four women
identiﬁed during acute HIV-1 infection in Durban, South Africa, through twice-weekly
screening of high-risk participants. In contrast to chronically HIV-1-infected patients, we
found that at the earliest phases of infection in these four participants, the majority of viral
DNA genomes are intact, lack APOBEC-3G/F-associated hypermutations, have limited
genome truncations, and over one year show little indication of cytotoxic T cell-driven
immune selections. Viral sequence divergence during acute infection is predominantly fueled
by single-base substitutions and is limited by treatment initiation during the earliest stages of
disease. Our observations provide rare longitudinal insights of HIV-1 DNA sequence proﬁles
during the ﬁrst year of infection to inform future HIV cure research.
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Current HIV-1 antiretroviral treatment successfully controlsviral replication and has transformed HIV-infection froma fatal illness to a manageable chronic condition1. How-
ever, despite suppression of viral replication during treatment,
studies have shown that pools of latent reservoirs persist long-
term and may fuel viral rebound when antiviral suppression
treatment is interrupted2–4. These reservoirs are extremely dur-
able, not susceptible to therapeutic effects of currently available
antiretroviral agents and have been refractory to recent experi-
mental treatment approaches5.
Recent results suggest that such viral reservoirs are established
extremely early in the infection process4–8, possibly even prior to
detection of viremia in blood, and indicated that treatment
initiation in humans during the earliest stages of infection does
not prevent viral reservoir seeding8. Nevertheless, multiple studies
have demonstrated that early treatment can serve to limit reser-
voir sizes and diversity9–12, preserve immune functions10,13–15,
and in some cases was associated with virologic control
when treatment was interrupted16,17. A common goal of current
HIV-1 cure research is to understand the complexity and evo-
lutionary dynamics of viral reservoir cells, and to develop inter-
ventional strategies that destabilize or reduce their long-term
persistence18–20.
Thus far, studies to evaluate longitudinal decay dynamics of
early HIV-1 reservoirs have relied on PCR-based techniques such
as quantitative PCR (qPCR) and/or droplet digital PCR (ddPCR)
which both capture short portions of HIV-1 DNA genomes.
These methods are limited by the fact that over 90% of the viral
DNA genomes in long-term treated chronically-infected patients
are defective and replication-incompetent, and are more likely to
represent fossils of the replicative history of HIV-1 in a given
patient, rather than a functionally-relevant viral reservoir able to
fuel rebound viremia21. A selective assessment of genome-intact
HIV-1 proviruses would be highly informative for understanding
mechanisms of reservoir establishment, but require complex
molecular analysis techniques ideally based on near full-genome
sequencing of individual proviral species. A pioneering study by
Bruner et al. analyzed peripheral blood mononuclear cells
(PBMCs) in nine patients who initiated antiretroviral treatment
early during the disease course (17–97 days after presumed date
of infection) and found that only 2–10% of proviruses had intact
genomes, thus inferring that defective proviruses rapidly accu-
mulate during acute HIV-1 infections7. Yet, these studies were
conducted with cell samples collected 10–145 months post-
treatment initiation, and therefore may not reﬂect viral DNA
compositions during acute HIV-1 infection but might instead be
inﬂuenced by the decay kinetics of HIV-1 DNA sequences fol-
lowing treatment initiation. For this and other reasons, the
structure and composition of intact HIV-1 DNA sequences
detectable within days after HIV-1 transmission remain unknown
and require further investigation.
In this report, we provide a longitudinal evaluation of HIV-1
DNA sequences in four subtype C HIV-1-infected individuals
identiﬁed at stages II and V of acute infection (according to the
classiﬁcation system of Fiebig et al.22). These four patients are
enrolled in the FRESH (Females Rising through Education,
Support, and Health) cohort23,24 in Durban, South Africa, in
which young women at high risk for acquiring HIV-1 infection
are encouraged to undergo HIV-1 screening tests twice a week. If
HIV-1 infection is documented, these individuals are offered to
start antiretroviral treatment immediately, frequently within
hours after positive screening test results, and are invited to
participate in an observational cohort study focusing on long-
itudinal evaluations of clinical, virological and immunological
parameters. This study design has enabled us to identify indivi-
duals within days after HIV-1 transmission, and to capture
HIV-1 DNA sequence proﬁles detectable at these extremely early
stages of infection, both in individuals who opted for immediate
treatment initiation and in persons who remained off-treatment.
Given that initiation of antiretroviral treatment during such
exquisitely early stages of viral infection may offer a unique
window of opportunity for future clinical interventions focusing
on HIV-1 cure and eradication, we here conduct in-depth ana-
lyses of the structure, composition, and longitudinal evolution of
proviral HIV-1 DNA sequences in four FRESH cohort partici-
pants. We observe that HIV-1 DNA genomes detected at the
earliest phase of infection, namely at Fiebig stage II (before
treatment initiation), consist predominately of genome-intact
viral DNA and have limited genome truncations; APOBEC-3G/F-
associated hypermutations are not observed in the limited sam-
pling depth. Furthermore, early HIV-1 DNA sequence divergence
at both Fiebig stage II and V is predominantly fueled by single-
base substitutions. Over 1 year of longitudinal follow-up in two
persistently viremic patients who remained untreated, genome-
intact viral DNA genomes show little indication of cytotoxic T
cell (CTL)-driven immune selections despite the presence of
HLA-alleles that have been associated with immune-mediated
viral escape mutations25,26.
Results
Patient characteristics. Four female individuals (Fig. 1 and
Supplementary Fig. 1) identiﬁed in primary HIV-1 infection were
non-randomly selected for this study to each represent a unique
clinical course based on their baseline acute infection stages and
their subsequent treatment status. All four patients (Pt) were
selected for having protective human leukocyte antigen (HLA)
genotypes (Table 1) to shed light on the dynamics of CTL-driven
viral evolution over time and were longitudinally followed for
approximately 1 year after infection. Pt 1 and Pt 2 were both
captured at stage II of acute HIV-1 infection (Supplementary
Table 1): Pt 1 immediately initiated antiretroviral therapy
(tenofovir, emtricitabine, efavirenz, raltegravir) after ﬁrst detec-
tion of HIV-1 plasma viremia, with raltegravir withdrawn 90 days
after viral suppression, whereas Pt 2 remained untreated
according to the treatment guidelines at the time of diagnosis for
the entire follow-up period of 328 days. In contrast, Pt 3 and Pt 4
were both captured at stage V of acute infection (Supplementary
Table 1): Pt 3 immediately received antiretroviral treatment
(tenofovir, emtricitabine, efavirenz) when plasma HIV-1 RNA
was ﬁrst detectable, whereas Pt 4 remained untreated for the
entire follow-up period of 332 days. Table 1 summarizes HLA
class I genotypes and peak/maximum viremia levels of each
patient. Each of the four patients had one protective HLA-B
allele26; only Pt 1 had an HLA-B allele associated with rapid
disease progression26. All four patients had detectable viremia at
one point during the study: In Pt 1, Pt 2, and P4, viremia peaked
at 105–107 copies/ml, whereas Pt 3 was likely detected post-peak
viremia at 42 days after the most recent negative HIV-1 PCR-test,
and our record showed a maximum at 150 copies of HIV-1 RNA/
ml at this time. Referring to Fig. 1, both patients who received
antiretroviral therapy (Pt 1 and Pt 3) achieved virologic sup-
pression at <46 days post-detection, whereas both untreated
patients (Pt 2 and Pt 4) demonstrated a spontaneous graduate 2-
log decrease of plasma viral load over 1 year, likely reﬂecting
natural restriction of HIV-1 replication via innate and adaptive
immune mechanisms. CD4 counts in all patients over the entire
study duration were consistently around 1000 cells/μL.
Intact HIV-1 DNA genomes predominate in acute infections.
In a cross-sectional analysis using PBMC collected at the earliest
available timepoints, we noted that HIV-1 DNA copies/million
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PBMC determined by ddPCR were substantially lower in the two
individuals identiﬁed during stage II of acute infection (Pt 1 and
Pt 2: 15 and 33 copies/million PBMC), relative to the two
remaining study persons diagnosed during stage V (Pt 3 and Pt 4:
480 and 2379 copies/million PBMC) (Fig. 1, earliest time point).
However, this approach for viral DNA quantiﬁcation relies on
ampliﬁcation of a short segment of the HIV-1 genome and does
not allow to accurately quantify the frequency of intact proviral
sequences which may evolve into functionally-relevant compo-
nents of the long-term HIV-1 reservoir. In fact, the majority of
viral sequences identiﬁed by ddPCR represent genome-defective
HIV-1 DNA products that result from the high error rate of the
viral reverse transcriptase and account for a considerable pro-
portion of HIV-1 DNA sequences detectable in individuals
undergoing antiretroviral therapy7,21. To address this, we per-
formed single-genome, near-full-length next-generation HIV-1
DNA sequencing, followed by a complex biocomputational ana-
lysis procedure (Fig. 2), to speciﬁcally quantify relative propor-
tions of genome-intact HIV-1 DNA sequences and viral DNA
species exhibiting genome defects precluding viral replication. At
each patient’s earliest sampling time point available, we sampled
4.1, 1.3, 1.8, and 0.8 million PBMCs from Pt 1 to Pt 4, respec-
tively, and detected a total of 42 genome-intact HIV-1 DNA
sequences at the earliest sampling time points. Consistent with
trends observed via ddPCR, absolute frequencies of genome-
intact HIV-1 DNA in patients identiﬁed during stage II were
lower than those at stage V (2.2 and 0.8 versus 3.4 and 31.1
genome-intact HIV-1 DNA copies per million PBMC, for
patients 1–4, respectively; Fig. 3a). Yet, relative contributions of
intact genomes to the total pool of HIV-1 DNA sequences were
markedly higher in stage II compared to stage V (82%, 100% in Pt
1 and 2, versus 15%, 35% in Pt 3 and 4; Fig. 3b). For comparative
purposes, we performed single-genome, near full-length HIV-1
DNA sequencing using PBMCs from three chronically-infected
patients who had uncontrolled viremia for >4, >7, and >12 years
of prior to initiation of ART and who underwent cell sampling at
18, 70, and 182 days after treatment onset. Notably, relative
proportions of intact HIV-1 sequences among all HIV-1 DNA
ampliﬁcation products were substantially smaller in these three
patients in comparison to all four patients identiﬁed in primary
HIV-1 infection (Pt 5: 1% (1/175), Pt 6: 5% (3/64), and Pt 7: 2%
(1/47)) (Fig. 3c). In these three patients, absolute frequencies of
Table 1 Clinical and immunogenetic characteristics of study patients
FRESH ID HLA-A HLA-A HLA-B HLA-B HLA-C HLA-C Stage of acute HIV-1 infection at
time of earliest sample collection
Peak/maximum
viremia (copies/ml)
Patient 1 127-33-0897-651 03:01 29:02 44:03a 58:02b 06:02 07:01 Stage II 2.6 × 106
Patient 2 127-33-0397-268 01:01 66:01 39:10 81:01a 12:03 18 Stage II 7.7 × 105
Patient 3 127-33-0611-442 68:02 74 15:03 57:02a 02:10 18 Stage V 150
Patient 4 127-33-0262-198 23:01 30:01 15:10 58:01a 03:02 16:01 Stage V 5.7 × 107
aHLA I alleles associated with protection1
bHLA I allele associated with disease-susceptibility1



















































































































































Fig. 1 Clinical and virological characteristics of the four study participants. Longitudinal trends of viral load (dashed black lines), CD4 counts (dotted black
lines), absolute frequencies of genome-intact HIV-1 per million PBMCs (orange lines), absolute frequencies of genome-defective HIV-1 (light green lines),
and total HIV-1 DNA burden determined by ddPCR (blue lines) are shown. Acute HIV-1 infection was staged according to the classiﬁcation system of Fiebig
et al.22
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total HIV-1 DNA were 48.9, 39.3, and 35.9 copies per million
PBMC, and absolute frequencies of genome-intact HIV-1 DNA
were 0.3, 1.8, and 0.8 copies per million PBMC respectively
(Supplementary Table 2). Together, these results suggest a pre-
dominance of genome-intact HIV-1 DNA sequences during early
stages of HIV-1 infection.
Spectrum of defective HIV-1 DNA genomes in acute infec-
tions. We subsequently conducted a detailed analysis of the
defective viral sequences observed in the four study patients with
primary HIV-1 infection. Among the defective genomes detec-
ted, no APOBEC-3G/3F-hypermutated HIV-1 DNA genomes
were observed at stage II after sampling 1.3–4.1 million PBMCs,
in contrast to 6% (2/35) and 6% (3/48) of hypermutated
sequences detected at stage V after sampling 0.8–1.8 million
PBMCs (Fig. 3d). This observation is limited by the small
number of total HIV-1 DNA genomes detected at stage II. Non-
hypermutated varieties of defective HIV-1 DNA genomes
detected at stage II included: One case of double premature stop
codons at amino acid positions 628 and 670 in Env (HXB2
coordinates), both attributable to TGG to TAG single-base
substitution mutations (Pt 1), and one case of a single large
internal deletion corresponding to HXB2 coordinate
7016–8912 spanning the V3 loop in gp120 to nef (Pt 1). No
defective viral genomes were detected at Pt 2’s initial analysis
timepoint during stage II of acute infection (Supplementary
Table 3, rows 1 and 4). In contrast, at stage V, non-hypermutated




Nested-PCR amplification of 
Near-full-length HIV genome
BIO-RAD ddPCR
 total HIV DNA quantificaiton







<8000 bp ≥ = 8000 bp
HIV
No primer
Psi indel ≥ = 15 bp
5′ defects Genome-intact HIV









Translation into amino acids
Yes primer
Agencount AMPure XP PCR 
product purification
Agarose gel electrophoresis
Amplified: HXB2 684–810 (127 bp)
Amplified: HXB2 638–9632 (8995 bp)
*fastq-derived de novo assembled 
consensus sequence
NCBI MEGA blast against HXB2







Total copies of HIV DNA
 per L extraction
Limiting dilution to single HIV 
DNA template per PCR reaction
a
b
Fig. 2 Experimental and computational determination of viral genome intactness. a Sample processing pipeline for the generation of near-full-length HIV-1
sequences via single-genome-ampliﬁcation. b Schematic representation of individual viral sequence analysis steps incorporated in the R-language
HIVSeqinR script used for the determination of viral genome intactness in this study. A stable release (ver2.6) used in this study is available in GitHub at
https://github.com/guineverelee/HIVSeqinR
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varieties of defective HIV-1 DNA genomes included: Two cases
of premature stop codons attributable to substitution mutations
at amino acid positions Env 832 and Gag 322, respectively (Pt 4),
and 72 cases of large internal deletions (29 from Pt 3 and 43 from
Pt 4; Supplementary Table 3, rows 8 and 12). In summary, viral
genome defects at stage V were different in composition com-
pared to stage II samples and included predominantly large
deletions (83% (29/35) and 90% (43/48) in Pt 3 and 4), followed
by APOBEC-3G/3F-associated hypermutations (6% (2/35) and
6% (3/48)) and premature stop codons from substitution
mutations (0% (0/35) and 4% (2/48)).
Longitudinal evolution of HIV-1 DNA after acute infection.
Overall, this study collected a total of 292 HIV-1 DNA sequences
in all four patients sequentially sampled over a 1-year follow-up
period (Fig. 4a). Absolute proportions of both genome-intact and
genome-defective viruses per million PBMCs sampled showed a
general trend of decreasing over the 1-year follow-up duration
(Fig. 4b, c). Relative proportions of genome-intact HIV-1 DNA
sequences also showed a general trend of decreasing over time,
while the proportions of other genome-defective categories varied
longitudinally (Fig. 4d). It should be noted that these observations
were limited by the low number of HIV-1 genomes that were
recovered at multiple time points from the blood samples avail-
able for testing (Supplementary Table 3). Among all 87 genome-
intact proviruses detected in the four patients during the ﬁrst year
of infection, 100% (Pt 1, 2, 3) and 87% (Pt 4) of the intra-host
genetic variations were attributed to single base substitution
mutation events; 13% of the intact genomes in Pt 4 contained
non-lethal insertion/deletion mutations (Fig. 5a). In both
untreated patients, sequence diversity increased over the follow-
up duration from a pairwise median of 8 bp differences between
intact genomes at baseline to 18 bp differences in Pt 2, and from 4
to 39 bp differences in Pt 4. In contrast, diversity among intact
proviral sequences over the follow-up duration decreased and/or
remained relatively constant in ART-treated patients from a
median of 3 to 6 bp differences in Pt 1, and from 3 bp to unde-
tectable in Pt 3 (Supplementary Table 4). In comparison, in a
chronically-infected patient (Pt 6, Supplementary Table 2), pair-
wise distance between intact viral genomes ranged from 172 to
235 bp; this analysis was not performed for Pt 5 nor Pt 7 because
only one intact genome was recovered from each of the two
patients. Interestingly, in Pt 1, whose regimen contained ralte-
gravir from the beginning of the antiretroviral treatment initia-
tion, a genome-intact provirus harboring a single-base
substitution at 1-month post-detection translated into Y143H, an
integrase inhibitor-associated resistance mutation27 (Fig. 5a).
Furthermore, no cases of complete sequence identity between
distinct intact or defective viral genomes were detected over the
entire 1-year study duration in all sequences derived from Pt 1
(19 sequences from all time points), Pt 2 (27), nor Pt 3 (53). In
contrast, three clusters of completely identical HIV-1 DNA
sequences were detected in Pt 4 at the time of diagnosis at stage V
and at subsequent time points (two clusters consisting of intact
genomes marked in Fig. 5a, b as Cluster 1 and 2, and one cluster
containing two identical sequences with large deletions, termed
Cluster 3). No viral lineage(s) became dominant over time
(Fig. 5b).
Cytotoxic T cell epitope diversity. Each patient in this study had
one protective HLA class I allele known to be statistically asso-
ciated with protection against disease progression25,26. To
investigate the inﬂuence of HLA class I-dependent immune
pressure on HIV-1 DNA sequences, we ﬁrst deﬁned regions in
the viral genomes that contained epitopes restricted by auto-
logous protective HLA class I alleles in each patient, using the Los
Alamos HIV Molecular Immunology Database28 as a reference.
Then, we subjected each intact viral genome to a search for
sequence variations consistent with CTL-driven escape mutations
in the pre-deﬁned epitopes. Speciﬁcally, CTL epitopes associated
with HLA-B 44:03, 81:01, 57:02, 58:01 in Pt 1–Pt 4, respectively
(Table 1), were examined longitudinally for evidence of mutations
away from viruses detected at the earliest sampling time points. In
total, we evaluated 67 distinct epitopes, including 15 epitopes in
Pt 1, 12 in Pt 2, 9 in Pt 3, and 31 in Pt 4 spanning all HIV proteins
from Gag to Nef. Over time, we did not observe evidence for viral
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Fig. 3 Cross-sectional analysis of HIV-1 DNA sequences at stage II versus
stage V of acute infections. a Absolute frequencies of intact viral genomes
detected per million PBMC in indicated study patients at the earliest
sampling time points. b Proportions of intact (blue) and defective (orange)
viral genomes at the earliest sampling time points available from each of
the four FRESH cohort participants. c Proportions of intact (blue) and
defective (orange) viral genomes from three chronically-infected
individuals who were sampled shortly post-therapy-initiation. d Spectrum of
defective HIV-1 DNA sequences at the earliest sampling time points
available from each of the four FRESH cohort participants
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Fig. 4 Longitudinal changes in HIV-1 DNA genotypic compositions. a Diagram reﬂecting a cross-sectional view of all 292 HIV-1 genomes presented in this
study from all four patients over all sampling time points (each horizontal line represents one viral genome). Navy blue lines represent intact HIV-1
genomes; other colors represent defective HIV genomes. Asterisk denotes sampling time points at stage II. Hash denotes sampling time points at stage V.
b Absolute frequencies of intact HIV-1 DNA sequences per million PBMCs during the 1st year of infection. c Absolute frequencies of defective HIV-1 DNA
sequences per million PBMCs during the 1st year of infection. d Relative proportions of HIV-1 DNA sequences during the 1st year of infection
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and Pt 2, 194/195 (99%) and 94/96 (98%) epitope sequences
remained identical over the 1-year follow-up time, respectively.
Also, in Pt 1 and Pt 2, CTL epitope sequences from defective viral
genomes shared close to 100% genotypic identity with those
derived from intact viral genomes and did not show obvious signs
of CTL-driven mutational escape over time. In Pt 3, intact gen-
omes were only detected at the earliest time point and no
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In contrast, three interesting sequence shifts occurred in Pt 4:
These three shifts were found exclusively in Nef in regions con-
taining well-deﬁned HLA-B*58:01-restricted epitopes listed in the
Los Alamos HIV Molecular Immunology Database28, including
KF9/AL9 (KAAFDLSFF, Nef position 82–90 and overlapping
AAVDLSHFL, Nef Position 83–91), YY9 (YTPGPGVRY, Nef
position 127–135), and YF9 (YPLTFGWCF, Nef position
135–143). For each of the three epitopes, one new mutated
sequence was detected, and all increased in prevalence from 0%
(0/26 intact genomes containing escape mutations) at baseline to
71% (5/7), 43% (3/7), and 43% (3/7), respectively, 1 year after
infection (Supplementary Table 5). In Pt 4, no other sequence
shifts were observed in the other 28/31 (90%) epitopes evaluated.
Discussion
In this study, we provide a comprehensive evaluation of early
HIV-1 DNA genome landscapes during the 1st year of infection.
In the context of the four patients examined and the number of
cells sampled, we observed that (i) most HIV-1 DNA genomes
detectable at stage II were genome-intact, (ii) single-base sub-
stitution mutations, likely attributable to errors due to reverse
transcriptase activities, were responsible for the majority of early
HIV-1 DNA genotypic diversity, (iii) host APOBEC-3G/3F
activity, as measured by the presence of hypermutated viral
genomes, was not observed in the earliest phase of infection but
increased in occurrence over time, (iv) viral genome truncation,
the most commonly observed type of defect in chronically-
infected patients receiving antiretroviral therapy7,21,29,30, was rare
in the earliest phase of infection but also increased over time, (v)
identical intact proviral sequences, suggestive of clonal pro-
liferation of HIV-1-infected CD4 T cells, were uncommon in the
earliest stages of infection, and ﬁnally, (vi) signs of CTL-mediated
immune selection pressure were unexpectedly weak over the ﬁrst
year of infection despite the presence of protective HLA-alleles.
Our study is foremost limited by our sample size and sampling
depth: we were only able to sample 0.4–4.1 million PBMCs per
sampling time point due to the extreme scarcity of blood samples
available from our study patients. Furthermore, each of the four
patients examined had unique and protective HLA-alleles, dif-
fered in treatment status (treated versus untreated), and also
varied in terms of clinical proﬁles including viral loads and CD4
counts. As such, our observations must be regarded as individual
patient proﬁles and should not be over-generalized. Nonetheless,
due to its longitudinal nature, our study may serve as a basis for
further investigations of viral DNA evolutionary dynamics during
and after acute HIV-1 infection.
Despite our limitations in sample size and sampling depth, this
study is, to our knowledge, the ﬁrst to longitudinally quantify
population evolutionary dynamics of HIV-1 DNA species in
hyperacute HIV-1 infection, speciﬁcally in the context of the
HIV-1 clade C epidemic in sub-Saharan Africa. In this context, it
is important to emphasize that in this study we describe snap-
shots of HIV-1 DNA genotypic compositions at the earliest stages
of infection; some of these infected cells, but not all, could become
future latent reservoirs, deﬁned as infected cells with tran-
scriptionally silenced HIV-1 genomes in patients undergoing
suppressive treatment. In addition, our near-full-length viral
genome sequencing method involved PCR ampliﬁcation span-
ning HXB2 coordinates 638 (Lys tRNA primer binding site) to
9632 (3′LTR R repeat), and therefore could theoretically amplify
both episomal 2-LTR HIV-1 DNA and integrated proviral gen-
omes. It has been shown that 2-LTR circles accumulate early on
in acute infections and decline after prolonged antiretroviral
treatment12. Therefore, we cannot exclude that proportions of the
HIV-1 DNA copies reported here represented extrachromosomal
rather than proviral HIV DNA.
One of the particularly intriguing ﬁndings from this study is
the high proportion of genome-intact viruses in the two stage II
samples. Such prominence of genome-intact viral genomes is
likely explained by active viral replication and suggests that viral
genome truncation is a relatively rare event among newly infected
CD4+ cells during acute viremia but increases proportion-wise
relative to intact viral genomes as the infection progresses. For
comparison, we sequenced viral genomes from three chronically-
infected patients shortly after therapy initiation, which demon-
strated profoundly reduced proportions of genome-intact viruses
relative to individuals with acute HIV-1 infection. These data
together imply that sustained viremia for prolonged periods of
time prior to treatment initiation may have already led to the
accumulation of a large number of defective proviruses. This
observation is consistent with previous reports by Bruner et al.
and Pinzone et al. demonstrating that defective viruses dominate
the viral reservoir landscape in chronically-infected patients7,31.
Further studies should aim to sample patients at much tighter
sampling intervals and with a much larger sample size in order to
elucidate the decay dynamics of genome-intact viral DNA.
In this study, we also detected no evidence of sequence-identical
viruses in three of the four patients. Previous studies have used
complete viral genome sequence homology to infer clonal
expansion of infected cells in chronically-infected patients29,30.
However, due to the high level of viral sequence homology
observed in this cohort, integration site analysis (using for
example a method described in ref. 32) should be used to examine
the presence or absence of clonal expansion during the ﬁrst year of
infection. Nevertheless, the absence of sequence-identical viral
sequences in three out of four of our patients may suggest that
clonal proliferation of HIV-1-infected CD4 T cells is not a fre-
quent phenomenon during the earliest stages of HIV-1 infection.
Of note, this low level of sequence-identical viruses in the FRESH
cohort represented a sharp contrast to our previously published
results from chronically-treated virologically-suppressed partici-
pants, in which 12/26 (46%) PBMC-derived intact HIV-1 DNA
genomes fell into sequence-identical, clonal clusters29.
Another interesting observation in this study is the lack of
potent CTL-driven evolution in patients with protective HLA
class I alleles, including two patients who did not receive anti-
retroviral therapy and were presumably exposed to stronger CTL-
dependent immune activity. This was demonstrated by the lack of
escape mutants in Pt 2 and by the incomplete dominance of
mutants in Pt 4. Furthermore, we only observed mutations in
HLA-B*58:01-restricted Nef epitopes among all HIV proteins
examined, consistent with prior studies demonstrating that Nef is
Fig. 5 Genetic variations among intact HIV-1 DNA genomes detected in this study. a Los Alamos HIV Sequence Database highlighter plots of all intact viral
genomes derived in this study across all time points. Each horizontal line represents an intact HIV-1 DNA genome detected in this study spanning HXB2
638-9632. For each patient, a random sequence from the earliest time point was selected to serve as the comparator against the rest of the intra-patient
viral genomes (top-most line in each patient, unmarked, master sequence). Vertical strokes represent bases that were different from the master sequence
(green A, blue C, orange G, red T, gray gap/deletion). Two genome-intact clonal clusters were detected in Pt 4 and were labeled as 1 and 2 on the right side
of the panel. b FastTree2 single precision approximately-maximum-likelihood phylogenetic tree of HIV-1 DNA intact genomes. This method was chosen to
resolve full-viral-genome sequences with extreme homology; branch lengths were likely inﬂated. Sequence-identical viral genomes were marked with (*)
and (**)
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a predominant target for HIV-1-speciﬁc CTL during early stages
of HIV-1 infection33. The lack of CTL-driven selective pressure
outside of Nef during the ﬁrst year of infection raises important
questions about the roles of CTLs for shaping the proviral
reservoirs during the course of infection.
In summary, we have provided an in-depth longitudinal eva-
luation of HIV-1 DNA genome compositions during the ﬁrst year
of infection and have shed light on factors that shaped early HIV-
1 DNA genotypic landscapes in four patients. The recent ﬁnding
that treatment initiation as early as stage I, followed by a median
2.8 years of suppressive treatment, would not eliminate persisting
viral reservoirs8 stresses that an extremely small number of
infected cells with genome-intact HIV-1 can result in virologic
rebound in the absence of treatment. As such, understanding the
properties of this small and obscure reservoir as well as host
factors associated with its survival and persistence34 should be one
of the most prioritized goals of HIV-1 reservoir and cure research.
In this context, it is important to stress that our study focuses on
HIV-1 DNA genotypes sampled during the earliest year of
infection; viral and host characteristics of infected cells that sur-
vive and persist long-term under suppressive therapy remain
undeﬁned, and should be further characterized by longitudinal
sampling that extend beyond the time frame of the current study.
Methods
Ethics statement. This study was approved by the Biomedical Research Ethics
Committee of the University of KwaZulu-Natal and the Institutional Review Board
of Massachusetts General Hospital. All participants provided written informed
consent.
Cohort description. The FRESH cohort is an observational, prospective cohort
launched in 2012 in Umlazi, Durban, South Africa where high-risk HIV-negative
women aged 18–23 were recruited to received twice-weekly HIV-1 RNA PCR
testing by ﬁnger prick during 96 weeks of surveillance, later revised to 48 weeks.
The study design incorporated a socioeconomic empowerment intervention to
address challenges that affect young women in this setting that may contribute to
increased HIV acquisition risk23,24,35. Following detection of acute HIV-1 infec-
tions, PBMCs were collected at weekly intervals for a month, then every 2 weeks for
2 months and monthly thereafter for 1-year post infection. As of August 2018, 946
women were enrolled; 72 were identiﬁed with acute HIV-1 infection. “Acute HIV
infection” was deﬁned as a new plasma HIV-1 RNA detection, that was positive on
repeat testing with an evolving HIV-1 Western blot pattern (prior to development
of a p31 band). Acute infection staging according to the classiﬁcation of Fiebig
et al.22 was based on plasma HIV-1 RNA, plasma p24 antigen (p24 Ag), fourth
generation HIV enzyme immunoassay (EIA) and Western blot (WB) and deﬁned
as follows: stage I (RNA+, p24 Ag−, EIA−, WB−); stage II (RNA+, p24 Ag+, EIA
+ or −, WB-); stage III (RNA+, p24 Ag+ or −, EIA+, WB- or indeterminate);
stage IV (RNA+, p24 Ag+ or −, EIA+, WB indeterminate or +); stage V (RNA+,
p24 Ag+ or −, EIA+, WB+ without p31 band)22,35,36 (Supplementary Table 1).
Peak viremia was deﬁned as the highest viral load detected during the initial viral
load increase/decline stage. No participants were recruited for this speciﬁc study;
banked, cryopreserved PBMC samples were used.
Single-template viral genome ampliﬁcation. Total PBMC collected from each
patient at each time point were independently subjected to DNA extraction using
DNeasy Blood & Tissue Kits (QIAGEN). Total HIV-1 DNA and host cell con-
centrations in the DNA extracts were estimated using BIO-RAD ddPCR, using
primers and probes covering HIV-1 5′ LTR-gag HXB2 coordinates 684–81037
(forward primer 5′-TCTCGACGCAGGACTCG-3′, reverse primer 5′-TACTGA
CGCTCTCGCACC-3′ probe/56-FAM/CTCTCTCCT/ZEN/TCTAGCCTC/
31ABkFQ/, and human RPP30 gene38 forward primer 5′-GATTTGGACCTGC
GAGCG-3′, reverse primer 5′-GCGGCTGTCTCCACAAGT-3′, probe/56-FAM/
CTGACCTGA/ZEN/AGGCTCT/31ABkFQ/). ddPCR was performed using the
following thermocycler program: 95 °C for 10 min, 45 cycles of 94 °C for 30 s and
60 °C for 1 min, 72 °C for 1 min. The droplets were subsequently read by the BIO-
RAD QX100 droplet reader and data were analyzed using QuantaSoft software
(BIO-RAD). Extracted DNA was diluted according to ddPCR results and Poisson
distribution statistics, so that the statistical probability of one HIV-1 genome
template per PCR reaction was 85.7%. This was followed by HIV-1 near-full-
genome ampliﬁcation using a single-amplicon nested PCR approach29,39 (ﬁrst-
round nested-PCR: forward primer 5′-AAATCTCTAGCAGTGGCGCCCGAA
CAG-3′, reverse primer 5′-TGAGGGATCTCTAGTTACCAGAGTC-3′; second-
round nested-PCR: forward primer 5′-GCGCCCGAACAGGGACYTGAAA
RCGAAAG-3′, reverse primer 5′-GCACTCAAGGCAAGCTTTATTGAGGCT
TA-3′). One unit of Platinum Taq (Invitrogen) per 20 μL reaction was incubated
with 1× reaction buffer, 2 mM MgSO4, 0.2 mM dNTP, 0.4 μM each of forward and
reverse primers, and subjected to the following PCR program: 2 min at 92 °C, 10
cycles [10 s at 92 °C, 30 s at 60 °C, 10 min at 68 °C], 20 cycles [10 s at 92 °C, 30 s at
55 °C, 10 min at 68 °C], 10 min at 68 °C, 4 °C inﬁnite hold. Figure 2a illustrates the
sample processing workﬂow.
MiSeq (Illumina) deep sequencing and viral bioinformatics. All PCR amplicons
detectable by gel electrophoresis were subjected to Illumina library preparation via
shearing-based adaptor-ligation-based technology and MiSeq sequencing, followed
by de novo assembly of the resulting small reads in collaboration with the Mas-
sachusetts General Hospital CCIB DNA Core. In this study, consensus FASTA
sequences derived from assembled contigs were screened for defects in the viral
genomes via an in-house sequence analysis pipeline termed HIVSeqinR (version
2.6). Figure 2b outlines the bioinformatics workﬂow. The ﬁrst key step in HIV-
SeqinR was the mapping of each viral genome against the reference genome HXB2
with local megablastn from the NCBI blast+ suite40,41 to remove any non-HIV
sequences derived from non-speciﬁc ampliﬁcations at the PCR step. Since mega-
blast only extends an alignment when there is an exact match of 28 base pairs (bp),
it would therefore detect junctions of any internal genome breakages; in contrast,
high-diversity regions such as the variable regions in env may not map. To
accommodate for such natural HIV genotypic diversity, we deﬁned any sequence to
be HIV if ≥80% of the total contig length mapped to HXB2. Subsequently, viral
genome defects were identiﬁed in the order of (i) large internal deletion(s) deﬁned
as sequence length <8000 bp (LargeDeletion), (ii) internal inversions or genome-
scrambling without inversions (InternalInversion or Scramble), (iii) APOBEC-3G/
3F-associated hypermutations (Hypermut) using a within-pipeline adaptation of
the Los Alamos Hypermute 2.0 web tool42, (iv) presence of premature stop codons
and/or insertions or deletions in any of HIV’s essential genes gag, pol or env that
would result in amino acid sequences <95% or >120% of expected lengths relative
to HXB2 (PrematureStop), and (v) indels at the 5′ packaging signal region that
accumulatively exceeded 15 bp relative to HXB2 (5DEFECT). Any HIV-1 proviral
genomes that do not have any of these pre-deﬁned defects are classiﬁed as “Intact.”
All other sequences that did not satisfy the above defectiveness classes were marked
“Check” to alert users to manually examine the genome. Finally, a key feature of
HIVSeqinR is our method used to translate HIV-1 genes. For each gene, individual
gene regions are deﬁned by recording ﬂanking start and stop codon coordinates
guided by gene-speciﬁc nucleotide alignment; resulting sequences are subsequently
degapped before translation. This method serves to avoid mis-translation that
arises from common cases such as GG-CCCAA-TT which would be at risk for false
translation to X-Pro-X-X (despite usage of codon alignment) instead of the correct
translation to Gly-Pro-IIe. All multiple sequence alignments in this study were
performed using MUSCLE43 or MAFFT44. Phylogenetic distances between
sequences were examined using FastTree 2.1.10 approximately-maximum-
likelihood single precision phylogenetic trees45 and/or Hamming distances calcu-
lated using the R-package Biostrings46. Primer binding sites were excluded from
analyses. All statistical tests and other genetic distance analyses in this study were
performed with R47 and Prism7 (GraphPad Software).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All raw HIV sequence data that support the ﬁndings of this study have been deposited in
GenBank (accession numbers MK643536–MK643827 [https://www.ncbi.nlm.nih.gov/
WebSub/?form=dwnld&sid=2204500&tool=genbank]). Data underlying all ﬁgures are
reported in Supplementary Tables 2, 3, and 4. The authors declare that all data
supporting the ﬁndings of this study are available within the paper and its Supplementary
Information ﬁles.
Code availability
The R-script of HIVSeqinR version 2.6 and all its documentations are freely available at
Github (https://github.com/guineverelee/HIVSeqinR). The output of HIVSeqinR consists
of six key ﬁles exported into the folder Results_Final: (i) a comma delimited (CSV) ﬁle
that contains translations of each gene from each sample, (ii) a CSV ﬁle that contains the
ﬁnal verdict for each contig (genome-intact or defective; type of defects), (iii) a FASTA
ﬁle containing all pairwise alignments of each viral gene against HXB2 in the nucleotide
space, (iv) a similar FASTA ﬁle in amino acid space, (v) a PDF representation of any
contigs that are ≥8000 base pairs (bp) and did not have any hypermutations nor internal
inversions, (vi) a multiple sequence alignment of all HIV contigs that are ≥8000 bp for
users to visually examine any unanticipated abnormalities. HIVSeqinR has been validated
to process subtype B and C HIV-1 DNA sequences.
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